HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Sellers Are ‘Essential’ Businesses During Pandemic, NPA Appeals To States

Executive Summary

As states and territories order closures of non-essential businesses, with supermarkets and pharmacies considered essential stores, NPA urges governors to consider the importance of its members’ and other natural health product firms’ contributions to their communities.

You may also be interested in...



US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes

It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.

Trade Groups Ask States To Keep Consumer Health Industry Lights On During Covid-19 Pandemic

“We have a responsibility to stay open and provide essential services, and that is exactly what we are going to do,” says NPA head Dan Fabricant. AHPA, CHPA, CRN and UNPA ask all US states to include VMS retailers and other nutritional supplement stores as part of “critical infrastructure” the Trump administration said must continue operating as the country responds to the Covid-19 pandemic.

Coronavirus Drives TCM Sales In China, Clouds Global Consumer Health Outlook

Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel